Works matching DE "SODIUM-glucose cotransporter 2 inhibitors"
Results: 1976
Safety and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Older Adults with Variable Disease States: A Meta-analysis of Large Placebo-Controlled Trials: Safety and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Older Adults...: S. A. Shah et al
- Published in:
- Drugs & Aging, 2025, v. 42, n. 3, p. 195, doi. 10.1007/s40266-025-01183-8
- By:
- Publication type:
- Article
Factors Associated With Sacubitril/Valsartan Continuation and the Methods of Combining Heart Failure Medications in Patients With Heart Failure.
- Published in:
- Annals of Pharmacotherapy, 2025, v. 59, n. 4, p. 301, doi. 10.1177/10600280241277354
- By:
- Publication type:
- Article
The impact of metformin on kidney disease progression and mortality in diabetic patients using SGLT2 inhibitors: a real-world cohort study.
- Published in:
- Cardiovascular Diabetology, 2025, v. 24, n. 1, p. 1, doi. 10.1186/s12933-025-02643-6
- By:
- Publication type:
- Article
Effectiveness and Safety of Sodium-Glucose Cotransporter-2 Inhibitor Continuation in Patients With Type 2 Diabetes and Late-Stage Chronic Kidney Disease.
- Published in:
- Journal of Pharmacy Technology, 2025, v. 41, n. 2, p. 65, doi. 10.1177/87551225241302731
- By:
- Publication type:
- Article
Successful renal replacement therapy of extreme ertugliflozin and alcohol induced euglycaemic ketoacidosis.
- Published in:
- Acta Diabetologica, 2025, v. 62, n. 3, p. 433, doi. 10.1007/s00592-024-02417-8
- By:
- Publication type:
- Article
Generalizability and treatment with sodium-glucose co-trasporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes: an assessment using an Italian primary care database.
- Published in:
- Acta Diabetologica, 2025, v. 62, n. 3, p. 343, doi. 10.1007/s00592-024-02359-1
- By:
- Publication type:
- Article
Diabetic Ketoacidosis and the Use of New Hypoglycemic Groups: Real-World Evidence Utilizing the Food and Drug Administration Adverse Event Reporting System.
- Published in:
- Pharmaceuticals (14248247), 2025, v. 18, n. 2, p. 214, doi. 10.3390/ph18020214
- By:
- Publication type:
- Article
Renal Abscess Associated with SGLT2 Inhibitors Administration in Heart Failure Without Other Previous Risk Factors: A Case Report.
- Published in:
- Biomedicines, 2025, v. 13, n. 2, p. 389, doi. 10.3390/biomedicines13020389
- By:
- Publication type:
- Article
SGLT2 Inhibitors: The First Endothelial-Protector for Diabetic Nephropathy.
- Published in:
- Journal of Clinical Medicine, 2025, v. 14, n. 4, p. 1241, doi. 10.3390/jcm14041241
- By:
- Publication type:
- Article
Diabetes Mellitus in Kidney Transplant Recipients: New Horizons in Treatment.
- Published in:
- Journal of Clinical Medicine, 2025, v. 14, n. 4, p. 1048, doi. 10.3390/jcm14041048
- By:
- Publication type:
- Article
Sodium–Glucose Cotransporter 2 Inhibitors and Lower-Extremity Amputation: Is the Guilty Verdict Valid?
- Published in:
- Diabetes Care, 2025, v. 48, n. 3, p. 338, doi. 10.2337/dci24-0101
- By:
- Publication type:
- Article
Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a Randomized Crossover Trial.
- Published in:
- 2025
- By:
- Publication type:
- Letter
Advances in sodium-glucose transporter protein 2 inhibitors and tumors.
- Published in:
- Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1522059
- By:
- Publication type:
- Article
The Potential of SGLT2 Inhibitors to Counteract Anemia in Patients with Heart Failure: The Potential of SGLT2 Inhibitors to Counteract Anemia in Patients with Heart Failure: Kow et al.
- Published in:
- 2025
- By:
- Publication type:
- Letter
Update on the Efficacy and Safety of Sodium–Glucose Co-Transporter 2 Inhibitors in Patients with Chronic Diseases: A Systematic Review and Meta-Analysis.
- Published in:
- Medicina (1010660X), 2025, v. 61, n. 2, p. 202, doi. 10.3390/medicina61020202
- By:
- Publication type:
- Article
Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages.
- Published in:
- International Journal of Molecular Sciences, 2025, v. 26, n. 4, p. 1670, doi. 10.3390/ijms26041670
- By:
- Publication type:
- Article
SGLT-2 inhibitors are beneficial in reducing the risk of thyroid cancer: findings from a Mendelian randomization study.
- Published in:
- Acta Diabetologica, 2025, v. 62, n. 2, p. 185, doi. 10.1007/s00592-024-02344-8
- By:
- Publication type:
- Article
Sodium–glucose cotransporter 2 (SGLT2) inhibitors and risk of chronic kidney disease–mineral and bone disorders in patients with type 2 diabetes mellitus and stage 1–3 chronic kidney disease.
- Published in:
- Canadian Medical Association Journal (CMAJ), 2025, v. 197, n. 7, p. E178, doi. 10.1503/cmaj.240922
- By:
- Publication type:
- Article
Current updates of sodium-glucose cotransporter-2 inhibitor effects on atherosclerosis: a systematic review and meta-analysis of randomized controlled trial.
- Published in:
- Acta Angiologica, 2024, v. 30, n. 1, p. 1, doi. 10.5603/aa.98562
- By:
- Publication type:
- Article
Bexagliflozin in type 2 diabetes: a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 7, p. 241, doi. 10.1007/s40267-024-01098-1
- By:
- Publication type:
- Article
Sex-Related Disparities in Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Type 2 Diabetes and Heart Failure.
- Published in:
- Journal of Women's Health (15409996), 2023, v. 32, n. 11, p. 1219, doi. 10.1089/jwh.2023.0059
- By:
- Publication type:
- Article
Cover Feature: Diarylcuprates for Selective Syntheses of Multifunctionalized Ketones from Thioesters under Mild Conditions (Chem. Eur. J. 26/2022).
- Published in:
- Chemistry - A European Journal, 2022, v. 28, n. 26, p. 1, doi. 10.1002/chem.202201013
- By:
- Publication type:
- Article
Diarylcuprates for Selective Syntheses of Multifunctionalized Ketones from Thioesters under Mild Conditions.
- Published in:
- Chemistry - A European Journal, 2022, v. 28, n. 26, p. 1, doi. 10.1002/chem.202200474
- By:
- Publication type:
- Article
Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial)
- Published in:
- Cardiovascular Drugs & Therapy, 2025, v. 39, n. 1, p. 145, doi. 10.1007/s10557-024-07576-y
- By:
- Publication type:
- Article
Iron Status Screening in Individuals with Heart Failure Before Initiating Sodium-Glucose Cotransporter 2 Inhibitor Therapy: Is It Necessary?
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 4, p. 859, doi. 10.1007/s10557-023-07498-1
- By:
- Publication type:
- Article
Acute Biomechanical Effects of Empagliflozin on Living Isolated Human Heart Failure Myocardium.
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 4, p. 659, doi. 10.1007/s10557-023-07434-3
- By:
- Publication type:
- Article
Numbers Needed to Treat for Preventing Adverse Cardiovascular Outcomes for Sodium-Glucose Cotransporter 2 Inhibitors vs. Dipeptidyl Peptidase 4 Inhibitors: The Hong Kong Diabetes Study.
- Published in:
- 2024
- By:
- Publication type:
- Letter to the Editor
Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Ventricular Repolarization Markers in Heart Failure with Reduced Ejection Fraction.
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 2, p. 327, doi. 10.1007/s10557-022-07396-y
- By:
- Publication type:
- Article
Dapagliflozin for Atrial Fibrillation.
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 1, p. 1, doi. 10.1007/s10557-024-07543-7
- By:
- Publication type:
- Article
Winding Down the Storm: Could Empagliflozin's Ion-Dependent Mechanisms Tackle the Ventricular Arrhythmia Burden in Chronic Chagas Cardiomyopathy?
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 1, p. 203, doi. 10.1007/s10557-023-07510-8
- By:
- Publication type:
- Article
The SGLT2i Dapagliflozin Reduces RV Mass Independent of Changes in RV Pressure Induced by Pulmonary Artery Banding.
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 1, p. 57, doi. 10.1007/s10557-022-07377-1
- By:
- Publication type:
- Article
Trimetazidine to Reduce Myocardial Fibrosis—Competing Interests with SGLT2 Inhibitors?
- Published in:
- 2023
- By:
- Publication type:
- Abstract
SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction.
- Published in:
- Cardiovascular Drugs & Therapy, 2023, v. 37, n. 5, p. 989, doi. 10.1007/s10557-022-07371-7
- By:
- Publication type:
- Article
Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Events, Stroke, and Mortality in Patients with Type 2 Diabetes.
- Published in:
- Cardiovascular Drugs & Therapy, 2023, v. 37, n. 4, p. 619, doi. 10.1007/s10557-022-07374-4
- By:
- Publication type:
- Article
Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
- Published in:
- Cardiovascular Drugs & Therapy, 2023, v. 37, n. 3, p. 561, doi. 10.1007/s10557-022-07319-x
- By:
- Publication type:
- Article
Empagliflozin Ameliorates Ouabain-Induced Na<sup>+</sup> and Ca<sup>2+</sup> Dysregulations in Ventricular Myocytes in an Na<sup>+</sup>-Dependent Manner.
- Published in:
- Cardiovascular Drugs & Therapy, 2023, v. 37, n. 3, p. 461, doi. 10.1007/s10557-021-07311-x
- By:
- Publication type:
- Article
Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 6, p. 1157, doi. 10.1007/s10557-021-07254-3
- By:
- Publication type:
- Article
SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 6, p. 1091, doi. 10.1007/s10557-021-07243-6
- By:
- Publication type:
- Article
Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 4, p. 619, doi. 10.1007/s10557-021-07190-2
- By:
- Publication type:
- Article
A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 4, p. 713, doi. 10.1007/s10557-021-07186-y
- By:
- Publication type:
- Article
The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 561, doi. 10.1007/s10557-021-07291-y
- By:
- Publication type:
- Article
Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 497, doi. 10.1007/s10557-021-07234-7
- By:
- Publication type:
- Article
Improved Erythrocyte Deformability Induced by Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetic Patients.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 1, p. 59, doi. 10.1007/s10557-020-07067-w
- By:
- Publication type:
- Article
Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms.
- Published in:
- Cardiovascular Drugs & Therapy, 2021, v. 35, n. 6, p. 1253, doi. 10.1007/s10557-021-07216-9
- By:
- Publication type:
- Article
Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
- Published in:
- Cardiovascular Drugs & Therapy, 2021, v. 35, n. 6, p. 1161, doi. 10.1007/s10557-021-07160-8
- By:
- Publication type:
- Article
Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus.
- Published in:
- Clinical & Experimental Nephrology, 2023, v. 27, n. 1, p. 44, doi. 10.1007/s10157-022-02277-y
- By:
- Publication type:
- Article
Comparison between sodium‐glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real‐world evidence study.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2024, v. 40, n. 3, p. 1, doi. 10.1002/dmrr.3784
- By:
- Publication type:
- Article
Predictors of efficacy of Sodium‐GLucose Transporter‐2 inhibitors and Glucagon‐Like Peptide 1 receptor agonists: A retrospective cohort study.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2024, v. 40, n. 2, p. 1, doi. 10.1002/dmrr.3727
- By:
- Publication type:
- Article
Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2023, v. 39, n. 6, p. 1, doi. 10.1002/dmrr.3682
- By:
- Publication type:
- Article
Real world evidence of clinical predictors of glycaemic response to glucose‐lowering drugs among Chinese with type 2 diabetes.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2023, v. 39, n. 4, p. 1, doi. 10.1002/dmrr.3615
- By:
- Publication type:
- Article